President Donald Trump on Thursday announced deals with pharmaceutical giants Novo Nordisk and Eli Lilly that would cut the cost of the lowest doses of their in-demand weight-loss drugs, lowering the barrier for new patients to access treatment.

Under the plan, Novo Nordisk said the lowest doses of Wegovy will cost $149 for a month's supply, if approved, and will extend across all the company’s direct-to-patient offerings. The company also confirmed plans to lower prices for its injectable drugs, including Wegovy and Ozempic, under Medicare Part D, Medicaid and self-pay channels. Novo Nordisk said it is reviewing its U.S. self-pay pricing and expects to announce updated offers for Wegovy and Ozempic in the coming weeks.

For self-pay patients, Lilly said it will offer Zepbound starting

See Full Page